Hypertonic Saline Enhances Gene Therapy Vector Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods for lung diseases, such as cystic fibrosis, face challenges in efficiently delivering therapeutic cargoes to target airway or alveolar epithelial cells, with existing agents being either non-FDA approved, toxic, or injurious to lung tissue.
Innovation Solution
The use of a hypertonic solution, specifically a hypertonic salt solution with a salt concentration ranging from about 1% to 8%, is introduced to enhance the delivery of gene therapy vectors by contacting cells with it before, after, or simultaneously with the vectors, thereby improving gene transfer efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If hypotonic solutions, EGTA, lysophosphatidylcholine, or chemical/mechanical injury methods are used to enhance gene transfer, then gene transfer efficiency is improved, but tissue toxicity and injury increase
Solution Approach 1:
The patent changes the tonicity parameter of the solution from hypotonic to hypertonic (greater than 290 mOsmol/L), which fundamentally alters the mechanism of action. Hypertonic solutions enhance gene transfer through osmotic effects that facilitate vector entry without the cytotoxic effects of hypotonic solutions, EGTA, or lysophosphatidylcholine.
Solution Approach 2:
The patent employs a simple, readily available hypertonic solution (such as saline with added salts) that can be easily prepared and disposed of, replacing complex or toxic chemicals like EGTA and lysophosphatidylcholine. This approach uses inexpensive, biocompatible materials that do not require special handling or disposal procedures.
2Productivity
If non-FDA approved agents are used to enhance gene transfer, then transduction efficiency increases, but regulatory approval and clinical applicability decrease
Solution Approach 1:
The patent leverages the existing FDA approval and clinical use of hypertonic saline solutions (commonly used in cystic fibrosis treatment) to enhance gene transfer. By using an already-approved therapeutic agent for a dual purpose, the invention eliminates the need for separate regulatory approval of the delivery vehicle,加速ating clinical translation.
3Productivity
If mechanical injury methods are used to enhance gene delivery, then vector entry is improved, but cell viability and tissue integrity deteriorate
Solution Approach 1:
The patent replaces mechanical injury methods (physical disruption of tissue) with a chemical/osmotic mechanism using hypertonic solutions. The osmotic gradient created by hypertonic saline facilitates vector entry through physiological processes rather than mechanical damage, preserving tissue integrity while achieving enhanced delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hypertonic solution significantly enhances the gene transfer efficiency of gene therapy vectors, including adenovirus, adeno-associated virus, and lentivirus, leading to improved transduction in both in vitro and in vivo models, particularly in cystic fibrosis transmembrane conductance regulator (CFTR) function restoration in cystic fibrosis cells.
Implementation Method 1
contacting said cells with a hypertonic solution before, after or simultaneously with said one or more gene therapy vectors
Data Source
AI summary
Method to enhance the delivery of one or more gene therapy vectors to cells comprising contacting said cells with a hypertonic solution before. after or simultaneously with said one or more gene therapy vectors.